A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 236
- Population
- ALL · 18 Years
- Duration
- 2026-03-31 to 2026-08-01
- Intervention
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO); Sham Subconjunctival Injection; Proparacaine Hydrochloride Ophthalmic Solution 0.5%; Lidocaine Hydrochloride Injection 2%
- Comparator
- Routine Anesthesia (Proparacaine + Subconjunctival Lidocaine)
- Outcomes measured
- Proportion of Participants Achieving Successful Ocular Surface Anesthesia — Immediately before and immediately after in…; Pain Score Immediately Before Intravitreal Injection — Immediately before intravitreal injection (Day 1); Pain Score Immediately After Intravitreal Injection — Immediately after intravitreal injection (Day 1); Pain Score at Evening Follow-Up — Evening of Day 1 (3-12 hours post-injection); Pain Score at 24 Hours Post-Injection — Day 2 (20-28 hours post-injection); Cumulative 24-Hour Pain Score — Day 1 through 24 hours post-injection; Change From Baseline in SPEED Questionnaire Score — Baseline, Evening Day 1, and Day 2 (20-28 hours); Change in Best-Corrected Visual Acuity — Time Frame: Baseline and Day 7 ± 2 days; Change in Intraocular Pressure — Time Frame: Baseline and Day 7 ± 2 days; Corneal Fluorescein Staining Score — Time Frame: Baseline, post-injection Day 1, and Day 7 ± 2 days; Incidence of Treatment-Emergent Adverse Events — Time Frame: Day 1 through Day 7 ± 2 days Unit: Number of participants…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.